Dr. Bruce A. Perkins is a clinician-researcher focused on type 1 diabetes. His current research interests are diabetic neuropathy (nerve damage), diabetic kidney disease and strategies to help improve blood sugar control which include the development of the artificial pancreas. Dr. Perkins obtained his MD and Internal Medicine Residency training at the University of Toronto and his Endocrinology subspecialty training at Harvard University and the Joslin Diabetes Center. He completed his Masters of Public Health in Epidemiology at the Harvard School of Public Health. Dr. Perkins joined the Leadership Sinai Centre for Diabetes at Mount Sinai Hospital in 2013 and is also an Associate Professor and Clinician-Scientist at the University of Toronto. Dr. Perkins is the co-chair of the 2016 and 2017 Diabetes Canada / Canadian Society of Endocrinology and Metabolism Professional Conference and the winner of Diabetes Canada’s 2015 Young Scientist Award.
Industry Expertise (3)
Health and Wellness
Health Care - Services
Areas of Expertise (7)
Type 1 Diabetes
Technologies in Diabetes Care
Diabetic Kidney Disease
William Randolph Hearst Research Fellow (professional)
Joslin Diabetes Centre
Brian Dufton Memorial Manuscript Award (professional)
The Hugh Tildesley Lectureship Award (professional)
University of British Columbia, Division of Endocrinology
CDA/CIHR Young Scientist Award 2015 (professional)
Canadian Institutes of Health Research and Diabetes Canada
Harvard School of Public Health: MPH, Public Health in Epidemiology
Harvard University and the Joslin Diabetes Cente: MD, Endocrinology
University of Toronto: MD, Internal Medicine
- Lunenfeld Tanenbaum Research Institute
- Toronto General Research Institute
- Mount Sinai Hospital
- University Health Network
- University of Toronto Division of Endocrinology and Metabolism
- University of Toronto Institute of Health Policy Management and Evaluation
- University of Toronto School of Graduate Studies
- Banting and Best Diabetes Center
- The Endocrine Society
- Canadian Society for Endocrinology and Metabolism
Media Appearances (1)
Many Type 1 diabetics living with disease 50-plus years
“I never expected to live this long.”
That’s a refrain that’s become increasingly common among people with Type 1 diabetes, many of whom were told as children or teens that their lives would likely be shortened due to a complication of the disease, such like kidney failure, heart attack or a stroke.
The objective of the study was to compare the efficacy of dual-hormone (insulin and glucagon) artificial pancreas, single-hormone (insulin alone) artificial pancreas, and conventional insulin pump therapy.
Cardiac autonomic neuropathy predicts future adverse renal outcomes in the general population. This study sought to determine its relationship with early progressive renal decline in type 1 diabetes.
This study evaluated the glycemic efficacy and safety of empagliflozin 25 mg daily in 40 patients treated for 8 weeks in a single-arm open-label proof-of-concept trial.
In vivo corneal confocal microscopy (IVCCM) has been proposed as a noninvasive technique to assess small nerve fiber structural morphology. This study investigated the structure-function relationship of small fibers in diabetic sensorimotor polyneuropathy (DSP).
This study aimed to determine the corneal confocal microscopy (CCM) parameter that best identifies diabetic sensorimotor polyneuropathy (DSP) in type 1 diabetes and to describe its performance characteristics.